Epalinges, Switzerland, March 5, 2026 – Novigenix SA, a leader in immunotranscriptomic diagnostics, today announced the formal spin-out and launch of Novigenix AI, a new precision medicine company dedicated to transforming therapy development through AI-powered immune intelligence. A Strategic Separation to Unlock Two High-Growth Markets The new AI spin-out separates Novigenix's colorectal cancer (CRC)